Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • Related Summaries

  • FDA Notice

  • Overview

  • Background

  • KeyboardArrowRight

    Drug Class Efficacy

    • Drug class efficacy for type 2 diabetes

    • Drug class efficacy for weight loss

    • Cardiovascular effects

    • Mortality effects

  • KeyboardArrowRight

    Exenatide

    • Prescribing information (exenatide)

    • Efficacy (exenatide)

    • Comparative efficacy (exenatide)

    • Dose comparisons (exenatide)

  • KeyboardArrowRight

    Liraglutide

    • Prescribing information (liraglutide)

    • Efficacy (liraglutide)

    • Comparative efficacy (liraglutide)

  • Semaglutide

  • Lixisenatide

  • Albiglutide

  • Dulaglutide

  • KeyboardArrowRight

    Investigational GLP-1 Receptor Agonists

    • Exenatide

  • Adverse Effects

  • KeyboardArrowRight

    Guidelines and Resources

    • Guidelines

    • Review articles

  • KeyboardArrowRight

    References

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Deputy Editor
Alan Ehrlich MD, FAAFP
KeyboardArrowDown
Affiliations

Executive Editor, DynaMed; Associate Professor of Family Medicine, University of Massachusetts Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Ehrlich declares no relevant financial conflicts of interest.

CheckCircle

top